ECOR electroCore, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$6.4

Period return

-0.64 (-9.09%)

Volume

78.2K

2026-07-21O $6.28 H $6.51 L $5.99 C $6.4MA5 $6.03MA20 $7.18MA60 $7.59MA120 $7.02

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 05.Highin 15 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2026. 01. 26.LowBUY6 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 03. 31.Mediumlast year
2026년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2025. 03. 14.LowBUYlast year
Ladenburg Thalmann: Buy
US analyst rating / recommendation change.
2025. 03. 13.LowBUYlast year
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2024. 12. 18.LowBUY2 years ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2024. 09. 30.Medium2 years ago
2025년 3분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2024. 06. 30.Medium2 years ago
2025년 2분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2024. 03. 31.Medium2 years ago
2025년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $19.17 · 5 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Sector: Healthcare
Industry: Medical Devices
HQ: Rockaway, NJ, United States
Fiscal year end: —
Employees: 83

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 05.	After market close (AMC)	—	—	—	$9.65M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.47	—	—	$6.72M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-1.19	—	—	$18.14M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.9	—	—	$11.58M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	19,121	$115.3K	0.00%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	19,421	$87.1K	0.00%	—	New position

electroCore, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 01. 26.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 03. 14.	Ladenburg Thalmann	—	Maintain	Buy → Buy	—	Ladenburg Thalmann: Buy
2025. 03. 13.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2024. 12. 18.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2024. 03. 14.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2024. 01. 22.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy